MwanzoIMGN • BMV
add
ImmunoGen Ord Shs
Bei iliyotangulia
$Â 268.50
Bei za mwaka
$Â 268.50 - $Â 268.50
Thamani ya kampuni katika soko
8.72B USD
Uwiano wa bei na mapato
-
Mgao wa faida
-
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 113.42M | 637.72% |
Matumizi ya uendeshaji wa biashara | 37.74M | 12.26% |
Mapato halisi | 30.75M | 139.54% |
Kiwango cha faida halisi | 27.11 | 105.36% |
Mapato kwa kila hisa | 0.10 | 132.26% |
EBITDA | 26.38M | 134.26% |
Asilimia ya kodi ya mapato | -3.94% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 605.54M | 95.64% |
Jumla ya mali | 822.10M | 129.13% |
Jumla ya dhima | 260.50M | 44.09% |
Jumla ya hisa | 561.60M | — |
hisa zilizosalia | 266.26M | — |
Uwiano wa bei na thamani | 127.25 | — |
Faida inayotokana na mali | 8.45% | — |
Faida inayotokana mtaji | 10.17% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 30.75M | 139.54% |
Pesa kutokana na shughuli | 2.77M | 104.31% |
Pesa kutokana na uwekezaji | -1.35M | -124.92% |
Pesa kutokana na ufadhili | 32.13M | 7,056.35% |
Mabadiliko halisi ya pesa taslimu | 33.55M | 152.12% |
Mtiririko huru wa pesa | -2.32M | 91.72% |
Kuhusu
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.
In November 2023, AbbVie, an American pharmaceutical company, announced it was buying ImmunoGen for $10.1 billion. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1981
Makao Makuu
Tovuti
Wafanyakazi
277
